Authors

Latest:

Therapeutic Ratio of Hypofractionation in Early Glottic Cancer: A Topic Worth Revisiting?

A retrospective experience suggests that early glottic cancer treated with HRT results in a higher incidence of acute toxicity without improved control compared to CRT delivered in an appropriate OTT.

Avital Harari, MD

Latest:

Researchers Investigate Increased Incidence of Thyroid Cancer in California

To investigate the possibility of environmental impacts as a predisposition for thyroid cancer, researchers sought to identify counties in California with possible geographic clustering of advanced thyroid cancer cases.

Avraham Eisbruch, MD

Latest:

Parotid Node Metastases in Locally Advanced Nasopharyngeal and Oropharyngeal Cancer: Implications for Radiotherapy Target Volume Delineation

The ipsilateral parotidean nodes may be at risk of metastatic involvement when bulky ipsilateral level II metastases and multilevel nodal disease are co-existent, possibly due to retrograde lymphatic drainage.

Axel F. Grothey, MD , Mayo Clinic

Axel Grothey, MD

Latest:

Dr. Grothey on the Potential Role of ctDNA as a Marker for Rechallenging Treatment in CRC

Axel Grothey, MD, discusses the potential utility of circulating tumor DNA as a marker for rechallenging patients with treatment in colorectal cancer.

Axel Grothey, MD, Mayo

Axel Grothey, MD, Mayo Clinic

Axel Grothey, MD, West Cancer Center & Research Institute

Latest:

Optimizing Treatment Strategies in Relapsed/Refractory Metastatic CRC

Axel Grothey, MD, West Cancer Center & Research Institute

Latest:

Open Questions and Future Directions in mCRC

Experts in CRC discuss questions and management of mCRC.

Axel Grothey, MD, West Cancer Center, University of Tennessee

Latest:

Management of Drug-Induced Interstitial Lung Disease

Axel Hauschild, MD

Latest:

Dr Hauschild on the Role of Adjuvant/Neoadjuvant Therapy in Melanoma Management

Axel Hauschild, MD, PhD, discusses the role of adjuvant and neoadjuvant therapy in melanoma, highlighting the utility of perioperative approaches.

Axel Hauschild, MD, PhD, University Hospital Schleswig-Holstein

Latest:

Long-Term Follow up for Adjuvant Dabrafenib Plus Trametinib in Stage III BRAF-Mutated Melanoma: Final Results of the COMBI-AD Study

COMBI-AD (NCT01682083) evaluated dabrafenib plus trametinib for patients with BRAF-mutated AJCC-stage III melanoma, and here the final results for RFS, distant-metastasis-free survival and overall survival are presented.

Axel Hauschild, MD, University Hospital Schleswig-Holstein

Latest:

Key Updates in Melanoma from ESMO 2020

Axel Hauschild, MD, University of Kiel

Axel Hoos, MD, PhD

Latest:

Dr. Hoos Discusses the Next Steps for Ipilimumab

Dr. Axel Hoos medical lead at Bristol-Myers Squibb Discusses the Next Steps for Ipilimumab

Ayad Hamdan, MD

Latest:

Dr. Hamdan on Choosing Among ABVD Versus A+AVD in Hodgkin Lymphoma

Ayad Hamdan, MD, discusses factors to consider when choosing between brentuximab vedotin (Adcetris), doxorubicin, vinblastine, and dacarbazine versus AVD plus bleomycin in patients with Hodgkin lymphoma.

Ayalew Tefferi, MD

Latest:

Dr. Tefferi on the Toxicity Profile of Imetelstat

Ayalew Tefferi, MD, hematologist, Mayo Clinic, Rochester, Minnesota, discusses the toxicity of imetelstat in patients with myelofibrosis.

Azadeh Namakydoust, MD, FACP

Latest:

Dr. Namakydoust on the Use of Next-Generation Sequencing in Lung Cancer

Azadeh Namakydoust, MD, FACP, thoracic oncologist, Memorial Sloan Kettering Cancer Center, discusses the use of next-generation sequencing (NGS) in lung cancer.

Aziz Nazha, MD

Latest:

Dr. Nazha on the Potential Role of Ropeginterferon Alfa-2b in Polycythemia Vera

Aziz Nazha, MD, discusses the potential role of ropeginterferon alfa-2b in polycythemia vera.

Azra Raza, MD

Latest:

Women in Oncology: Leukemia Therapies in Humans, for Humans

Judith Karp, MD, Azra Raza, MD, and Michelle M. Le Beau, PhD, discuss their proudest career accomplishments, including the investigation of potential treatments using a patient’s first cancerous cell, advances in cytogenetics, and a rational design for clinical trials involving cell cytokinetics..